The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19

Camila Rosat Consiglio(Science for Life Laboratory), Nicola Cotugno(University of Rome Tor Vergata), Fabian Sardh(Karolinska University Hospital), Christian Pou(Science for Life Laboratory), Donato Amodio(University of Rome Tor Vergata), Lucie Rodriguez(Science for Life Laboratory), Ziyang Tan(Science for Life Laboratory), Sonia Zicari(Bambino Gesù Children's Hospital), Alessandra Ruggiero(Bambino Gesù Children's Hospital), Giuseppe Rubens Pascucci(Bambino Gesù Children's Hospital), Veronica Santilli(Bambino Gesù Children's Hospital), Tessa M. Campbell(Karolinska Institutet), Yenan T. Bryceson(Karolinska Institutet), Daniel Eriksson(Karolinska University Hospital), Jun Wang(Science for Life Laboratory), Alessandra Marchesi(Bambino Gesù Children's Hospital), Tadepally Lakshmikanth(Science for Life Laboratory), Andrea Campana(Bambino Gesù Children's Hospital), Alberto Villani(Bambino Gesù Children's Hospital), Paolo Rossi(University of Rome Tor Vergata), Nils Landegren(Uppsala University), Paolo Palma(University of Rome Tor Vergata), Petter Brodin(Karolinska University Hospital)
Cell
September 6, 2020
Cited by 898Open Access
Full Text

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is typically very mild and often asymptomatic in children. A complication is the rare multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19, presenting 4-6 weeks after infection as high fever, organ dysfunction, and strongly elevated markers of inflammation. The pathogenesis is unclear but has overlapping features with Kawasaki disease suggestive of vasculitis and a likely autoimmune etiology. We apply systems-level analyses of blood immune cells, cytokines, and autoantibodies in healthy children, children with Kawasaki disease enrolled prior to COVID-19, children infected with SARS-CoV-2, and children presenting with MIS-C. We find that the inflammatory response in MIS-C differs from the cytokine storm of severe acute COVID-19, shares several features with Kawasaki disease, but also differs from this condition with respect to T cell subsets, interleukin (IL)-17A, and biomarkers associated with arterial damage. Finally, autoantibody profiling suggests multiple autoantibodies that could be involved in the pathogenesis of MIS-C.


Related Papers

No related papers found

Powered by citation graph analysis